LYSOGENE

company

About

Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.

  • 11 - 50

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€3M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders .

Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€3M
LYSOGENE has raised a total of €3M in funding over 2 rounds. Their latest funding was raised on Dec 24, 2021 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 24, 2021 Post-IPO Debt €3M 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
1
1
LYSOGENE is funded by 1 investors. European Investment Bank are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Post-IPO Debt